ineffective erythropoiesis
New therapies to restore red cell production for patients with inherited and acquired anemias
Restoring regulation of hepcidin - the link between genetics and erythropoiesis
Congenital and acquired anemias often start with genetic alterations, but end with impaired iron mobilization and metabolism. Disc is applying new insights in hepcidin biology to restore red cell production in conditions of both iron sequestration and iron overload.
learn moreNew life in hematology
Blood transfusions have been the foundation of hematology for 50 years, and the risk/benefit of regular transfusion is not appropriate for many patients. We recognize and seek to alleviate the challenges faced by individuals with congenital anemias, myelodysplastic syndrome, myeloproliferative disorders, thalassemia, and anemia of chronic disease – both those who receive transfusions and those who don’t.
more about our pipeline
Experienced team
Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.
learn more about our teamIn The News
John Quisel, JD, PhD Joins Disc Me…
Cambridge, Mass. – January 28, 2020 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red…
read more
Disc Medicine Completes $50 Millio…
Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic dise…
read more
Disc Medicine Expands Pipeline Foc…
Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies Cambridge, Mass. – October 29, 2019 – Disc Medicin…
read more